The advances in human epidermal growth factor receptor 2(HER-2) testing: the important role of translational medicine in treatment of breast cancer        LIU Yi, LIU Bing, JIANG Ze-Fei. Affiliated Hospital of Academy of Military Medical Sciences（307 Hospital），Beijing 100071, China
Corresponding  author： JIANG Ze-fei,E-mail：jiangzefei@medmail.com.cn
Abstract    Human epidermal growth factor receptor 2 (HER-2) status is considered to be a vital prognostic and predictive factor for therapeutic decision making in breast cancer.The conventional methods that used in clinical practice now are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Nevertheless, with the development of treatment concept in breast cancer, both IHC and FISH could not satisfy the clinical demand in real-time, dynamic and accuracy. HER-2 detection with HER-2 extra cellular domain (ECD) and circulating tumor cells (CTC) in blood were expected to settle the problems.